This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Media Advisory Date: Tuesday, July 1, 1997
Using the antibiotic erythromycin for treating community-acquired pneumonia (CAP) in most
outpatients aged 60 and under significantly reduces treatment costs compared with the use of
other antibiotics ($5.43 vs. $18.51), and has no adverse effect on medical outcomes. This finding
is consistent with the guideline recommendation from the American Thoracic Society (ATS),
which recommends erythromycin or other agents for those intolerant or allergic to this drug.
However, the ATS guideline does not recommend using erythromycin alone for CAP patients
over 60 years of age, or patients of any age with an additional illness. Researchers at the
University of Pittsburgh evaluating ATS guidelines found that using the recommended antibiotics
for these patients (most often amoxicillin/clavulanate, sulfamethoxazole-trimethoprim, or
cefuroxime) costs 10 times higher than using erythromycin or other non-recommended antibiotic
($73.50 vs. $7.50) and provides no increased effectiveness in medical outcomes.
This study, part of the Pneumonia Patient Outcomes Research Team (PORT) funded by the
Agency for Health Care Policy and Research, is described in the July 2 issue of the Journal of the
American Medical Association (JAMA). The PORT study provides the first objective data to
compare the clinical effectiveness and costs of antibiotic therapy with clinical guidelines for
About four-fifths of the four million Americans who develop pneumonia each year are treated as
outpatients. Direct outpatient treatment costs exceed $1 billion per year, of which roughly $100
million is spent on antibiotic therapy. More than 30 oral antibiotic medications have been
approved by the Food and Drug Administration for treatment of pneumonia, with costs ranging
from $0.01 to more than $6 per dose. This has contributed to wide variations in prescribing
patterns as well as increased antibiotic resistance.
The ATS guidelines were published in 1993 to improve the appropriateness of antibiotic
prescribing practices for pneumonia patients treated in an outpatient setting. The AHCPR-supported researchers evaluated the guidelines by comparing medical outcomes and prescription
costs among outpatients whose therapy was or was not consistent with ATS recommendations.
They looked at a total of 864 adult patients: 546 aged 60 or younger with no comorbidity, and
318 older than 60 years of age or any age with at least one comorbidity.
The findings were reported by Patrick P. Gleason, Pharm.D. and Michael J. Fine, M.D., M.Sc. of
the University of Pittsburgh's Center for Research on Health Care, and by co-investigators from
the University of Pittsburgh, Harvard Medical School and Dalhousie University.
For additional information contact AHCPR Public Affairs: Karen Carp, (301) 427-1858 (KCarp@ahrq.gov) or Salina V. Prasad, (301) 427-1864 (SPrasad@ahrq.gov). The JAMA
article is entitled "Medical Outcomes and Antimicrobial Costs With the Use of the American
Thoracic Society Guidelines for Outpatients With Community-Acquired Pneumonia." To arrange
interviews with Drs. Gleason and Fine, please contact Mark Kanny, University of Pittsburgh
Medical Center News Bureau, (412) 647-3555 (firstname.lastname@example.org).